Pramod Menon, MD
Interventional Cardiology · Covington, LANPI 1588620611
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by AstraZeneca at 34.3% of the total. Reporting peaked in 2021 at $13,634 and has fallen 75.8% since, to $3,297 in 2025.
Across 803 payments — averaging $66.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$18K
- Terumo Medical Corporation$12K
- Edwards Lifesciences$4K
- Medtronic$4K
- Boston Scientific$2K
- Abiomed$2K
- plus $11K from 52 others
Across 164 payments — averaging $872.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$104K
- Novo Nordisk AS$21K
- Bayer$18K
What the payments were for
- Consulting fees$10,52920%
- Speaking & faculty fees$17,35032%
- Travel & lodging$6371%
- Food & beverage$25,03347%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$18,089
- Navicross$8,608
- Impella$1,792
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$851
- Diamondback Peripheral$830
- COREVALVE EVOLUT R$675
- Edwards SAPIEN 3 Transcatheter Heart Valve$607
- SAPIEN 3 Ultra RESILIA$570
- R2P MISAGO$504
- SYMPLICITY G3$423
- CoreValve Evolut$407
- GLIDESHEATH SLENDER$291
- METACROSS OTW$274
- ELUVIA$273
- CARDIOMEMS$270
- GENERAL VASCULAR INTERVENTION$270
- EVOQUE$233
- VERQUVO$230
- Avalus$170
- OPTIMIZER SMART SYSTEM$162
How this compares
$53,614 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 384 | $380,829 |
| Repatha SureclickEvolocumab | 287 | $195,102 |
| CamzyosMavacamten | 22 | $168,728 |
| OzempicSemaglutide | 122 | $148,806 |
| XareltoRivaroxaban | 141 | $126,709 |
| FarxigaDapagliflozin Propanediol | 128 | $122,287 |
| EntrestoSacubitril/Valsartan | 148 | $121,017 |
| NexlizetBempedoic Acid/Ezetimibe | 69 | $62,283 |
| MounjaroTirzepatide | 41 | $52,032 |
| JardianceEmpagliflozin | 57 | $46,175 |
| Praluent PenAlirocumab | 59 | $37,606 |
| VascepaIcosapent Ethyl | 45 | $29,434 |
| MultaqDronedarone Hcl | 23 | $25,469 |
| NexletolBempedoic Acid | 29 | $25,112 |
| WegovySemaglutide | 16 | $20,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $851 | $380,829384 claims |
| Novo NordiskOzempic, Wegovy | $472 | $169,550138 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $322 | $168,72822 claims |
| AstraZenecaFarxiga, Brilinta | $18,378 | $133,945146 claims |
| Johnson & JohnsonXarelto | $684 | $126,709141 claims |
| NovartisEntresto | $571 | $121,017148 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $242 | $87,39598 claims |
| Lilly USA, LLCMounjaro | $34 | $52,03241 claims |
| Boehringer IngelheimJardiance | $130 | $46,17557 claims |
| MerckVerquvo, Januvia | $685 | $31,99739 claims |
| Sanofi-aventis U.S. LLCMultaq | $324 | $25,46923 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $59 | $15,77035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Covington
- George IsaCovington$81K
- Hamid SalamCovington$53K
- Frank ArenaCovington$19K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.